Drug intelligence / Profile preview

BT5

Development stage: Preclinical
Lead developer: Bycus Therapeutics
Modality: Small Molecules

Overview

BT5 is a novel small molecule therapeutic candidate currently under development by Bycus Therapeutics. It is positioned within the company's pipeline for the treatment of metabolic disorders. While specific details regarding its molecular target, mechanism of action, and clinical phase are not yet publicly available, BT5 is part of a broader portfolio of "Novel Molecules" aimed at addressing unmet needs in metabolic health, infectious diseases, and oncology. The drug represents a proprietary approach by Bycus Therapeutics to modulate metabolic pathways using small molecule chemistry.

Targets

NSD1 (Nuclear receptor-binding SET domain protein 1)NSD3

Beyond the preview

Go deeper on BT5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT5.

Explore the full profile